Pharmafile Logo

Inizio leaders featured in Forbes’ ‘Voices of Oncology’ to drive innovation in cancer care

September 24, 2025 |  

Inizio experts contribute to Forbes’ Voices of Oncology, highlighting our commitment to driving innovation in cancer care through advanced data analytics, cross-sector collaboration, and real-world impact for patients.

Voices-of-Oncology-Inizio

With over 30 years of deep-rooted expertise in oncology, we partner with our clients at each pivotal moment in their journey, unlocking value through a connected suite of capabilities. Today, we’re proud to announce that a number of our leaders in Inizio have been featured in Forbes’ Voices of Oncology, a collaboration that reflects our commitment to advancing cancer care.

Launching September 9, the ‘Voice of Innovation Partners’ chapter in Forbes’ ‘Voices of Oncology’ features contributions from:

Accelerating innovation in oncology through collaboration, data & technology

The ‘Voice of Innovation Partners’ chapter explores how innovation partners like Inizio harness advanced data analytics, cutting-edge technology, and cross-sector collaboration to:

  • Simplify complex challenges in oncology
  • Enhance decision-making across the cancer care continuum
  • Improve patient outcomes through real-world impact

The book is a powerful collection of insights from global experts and thought leaders, offering a shared perspective on how we can work better together to shape the future of oncology. Voices of Oncology is an initiative of the Oncology Voice Network (OVN), a new platform built to spark connection, share knowledge, and amplify solutions across pharma, biotech, academia, and patient advocacy.

Pre-order now: Forbes’ Voices of Oncology

Available to pre-order now via Amazon – explore the Voices of Oncology here. If you’re looking for a partner who can turn knowledge into action and accelerate the journey from breakthrough science to real-world impact, learn more about us.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Video: Self-pay and Emerging Markets

A key feature of emerging markets is that patients often have to pay for a high proportion of their healthcare costs themselves. For all but the most severe conditions, public...

News: Therapy Watch HCV expands into 4 additional EU markets

The HCV market has been growing and changing remarkably quickly and with the development of new and improving drugs, the treatment of HCV has moved on in a short space...

News: Research Partnership launches new patient report – Living with Ulcerative Colitis

Living with UC is a quantitative study conducted online amongst 325 patients, including both adult and paediatric patients diagnosed with ulcerative colitis in 5 EU markets (France, Germany, Italy, Spain...

Summer Intern experience at Research Partnership

We look for bright and inquisitive people who want to learn in a company that's pushing the boundaries of pharmaceutical market research

Double win at Communiqué 2016: Pegasus scoops awards for Consultancy of the Year (for the second time!) and Excellence in Media Relations

Pegasus, an Ashfield company, part of UDG Healthcare plc, is delighted to have won the prestigious Consultancy of the Year award at the 2016 Communiqué Awards in London. The judges...

Beyond Andrology: Trends in Men’s Health in Emerging Markets

Published in eyeforpharma July 2016 by Rachel Howard

Pharma & life sciences division growth allows Pegasus to fill three new senior positions

Pegasus has expanded its pharma & life sciences senior team by appointing a new Associate Director and promoting two members of the existing team to Account Directors.

Infographic: HIV Market Snapshot

Our latest HIV infographic, taken from data collected from syndicated tracking study Therapy Watch, reveals that more than 3 in 5 naive or switch patients are currently treated with a STR (single...

Infographic: The vaccine opportunity in Asia

As predicted, the vaccine market in emerging and developing countries has continued to expand. While the global vaccine market is expected to grow at around 12% annually over the next...

Webinar: What next for biosimilars?

Tuesday 19th July 15:00 BST/10:00 EDT/16:00 CEST